Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 1,957 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 1,957 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $64.63, for a total transaction of $126,480.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

William Richard White also recently made the following trade(s):

• On Friday, November 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $46.37, for a total transaction of $9,320.37.
• On Monday, November 4th, William Richard White sold 7,136 shares of Disc Medicine stock. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96.
• On Tuesday, October 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $51.31, for a total transaction of $10,313.31.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $64.46 on Thursday. The company’s fifty day moving average price is $54.74 and its 200 day moving average price is $47.94. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.15. As a group, analysts anticipate that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Institutional Trading of Disc Medicine

Institutional investors have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Disc Medicine by 38.7% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock worth $961,000 after buying an additional 5,458 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Disc Medicine by 17.6% during the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock worth $23,333,000 after buying an additional 70,983 shares in the last quarter. Barclays PLC grew its holdings in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock worth $1,972,000 after buying an additional 22,202 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Disc Medicine during the third quarter worth $445,000. Finally, Wellington Management Group LLP grew its holdings in shares of Disc Medicine by 4.8% during the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after buying an additional 83,731 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

IRON has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research note on Tuesday, November 5th. Wedbush restated an “outperform” rating and set a $83.00 price target (up previously from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Jefferies Financial Group started coverage on shares of Disc Medicine in a research note on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target on the stock. Finally, Scotiabank upped their price target on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $85.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.